Jazz Pharmaceuticals plc (JAZZ) — Analyst outlook / Analyst consensus target is. Based on 47 analyst ratings, the consensus is bullish — 41 Buy, 6 Hold.
The consensus price target is $207.86 (low: $170.00, high: $235.00), representing an upside of 3.4% from the current price $201.06.
Analysts estimate Earnings Per Share (EPS) of $20.31 and revenue of $4.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $9.06 vs est $20.31 (missed -55.4%). 2025: actual $-5.84 vs est $8.23 (missed -171%). Analyst accuracy: 0%.
JAZZ Stock — 12-Month Price Forecast
$207.86
▲ +3.38% Upside
Average Price Target
Based on 47 Wall Street analysts offering 12-month price targets for Jazz Pharmaceuticals plc, the average price target is $207.86, with a high forecast of $235.00, and a low forecast of $170.00.
The average price target represents a +3.38% change from the last price of $201.06.
Highest Price Target
$235.00
Average Price Target
$207.86
Lowest Price Target
$170.00
JAZZ Analyst Ratings
Buy
Based on 47 analysts giving stock ratings to Jazz Pharmaceuticals plc in the past 3 months
EPS Estimates — JAZZ
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $9.06
vs Est $20.31
▼ 124.1% off
2025
Actual –$5.84
vs Est $8.23
▼ 240.9% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — JAZZ
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $4.069B
vs Est $4.039B
▲ 0.7% off
2025
Actual $4.268B
vs Est $4.238B
▲ 0.7% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
